金吾财讯 | 据内部消息人士透露，丹麦制药公司诺和诺德(NVO)的印度团队因担心在印度市场上落后于竞争对手礼来公司(LLY)，正积极推动公司提前在印度推出其畅销减肥药Wegovy，以维持在全球减肥药市场的领先地位。原本诺和诺德计划在获得监管批准和充足供应后，可能在2026年将Wegovy引入印度市场。但最近，印度团队建议将上市时间提前至明年，与此同时，礼来公司也预计在同一时期在印度推出其减肥药Mounjaro。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.